This article first appeared in The Edge Malaysia Weekly on August 17, 2026 - August 23, 2026

UMediC Group Bhd (KL:UMC) has outperformed its peers in profit growth over the last three years since listing in 2022, driven by strategic expansion, acquisitions and increased manufacturing capacity.

Over the past four years, the group has steadily transformed from a medical device distributor into an integrated healthcare solutions provider, strengthening its position across the healthcare value chain while delivering consistent financial performance.

Its financial year ended July 31, 2023 (FY2023) marked a significant milestone in the group’s transformation. It adopted a two-pronged growth strategy by strengthening both its medical device marketing and distribution business while expanding its manufacturing operations. As production capacity increased and the group expanded into international markets, manufacturing became an increasingly important contributor to growth.

A key strategic move during the year was the acquisition of a 70% stake in Patho Solutions (M) Sdn Bhd, a specialist in laboratory equipment and consumables with expertise in histopathology, immunology and cytology. The acquisition broadened UMediC’s distribution portfolio and strengthened its presence in laboratory diagnostics, enabling the group to serve a wider range of healthcare institutions with more comprehensive solutions.

Growth continued in FY2024 as the group accelerated its diversification strategy through the incorporation of two specialised subsidiaries. Akiteck (Malaysia) Sdn Bhd, in which UMediC holds a 70% stake, focuses on the research, design and development of medical mounting solutions and carts. Its products support leading global manufacturers of patient monitoring, ultrasound, cardiotocography (CTG) and electrocardiogram (ECG) systems, creating opportunities to expand across Malaysia and the wider Southeast Asian market.

The group also established Ateria Medika Sdn Bhd, a 90%-owned subsidiary specialising in advanced medical devices and consumables for interventional cardiology and radiology. Together, these new businesses strengthened UMediC’s capabilities in high-value medical technologies while creating additional revenue streams.

On April 24, 2024, the group’s growth supported its successful transfer from Bursa Malaysia’s ACE Market to the Main Market, reflecting its operational maturity and stronger corporate standing.

UMediC took another major step forward in FY2025 with the completion of a major expansion of its manufacturing facility. The production floor increased from 30,000 sq ft to 50,000 sq ft, effectively doubling manufacturing capacity and enabling greater in-house production of proprietary medical consumables, including the HYDROX range of prefilled nebulisers and dehumidifiers, AIRDROX inhaler spacers and the FLEXIDROX Water for Inhalation Bag.

Beyond manufacturing, UMediC broadened its business model by introducing new healthcare service businesses, reinforcing its transition to an integrated healthcare ecosystem. The group established UMC Healthcare Centre, UMC Learning Centre and Rescue Medic Sdn Bhd, an 85%-owned subsidiary providing pre-hospital emergency medical services, ambulance operations and ambulance vehicle supply equipped with advanced medical devices. These additions complement the group’s existing strengths in medical products while extending its presence in healthcare services.

Today, UMediC’s core business spans the marketing and distribution of medical devices, manufacturing of proprietary medical consumables and the provision of after-sales services to public and private hospitals, healthcare providers and corporate customers. Through UMedic Healthcare Sdn Bhd, the group is also the authorised distributor for globally recognised brands including Philips, Mindray and GE, offering an extensive portfolio of critical-care and high-value medical equipment.

The group’s expansion strategy has supported its financial performance. Net profit stood at RM10.3 million in FY2023, RM9 million in FY2024 and RM8.1 million in FY2025, compared with RM6.4 million in FY2022. Based on the awards methodology, this represents a three-year compound annual growth rate (CAGR) of 4.9% despite operating in a highly competitive healthcare industry.

These contributed to UMediC’s strong return on equity of 17.84% in FY2023, 13.32% in FY2024 and 10.7% in FY2025, resulting in a weighted three-year ROE of 12.9%. 

UMediC’s share price, however, has been trending downwards, from 78.5 sen on March 31, 2023, to 61.2 sen a year later, 44 sen in 2025, and 29.5 sen as at March 31, 2026, in line with its moderating profit.

UMediC’s strategy to expand beyond its traditional marketing, distribution and manufacturing business into a broader healthcare ecosystem that combines healthcare products and services, appears to be bearing fruit. Its aim to drive growth through innovation, strategic acquisitions, expanded manufacturing capacity and complementary healthcare businesses continues to strengthen its position as a comprehensive healthcare solutions provider in Malaysia and the region. 

Save by subscribing to us for your print and/or digital copy.

P/S: The Edge is also available on Apple's App Store and Android's Google Play.